BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 24937264)

  • 1. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
    Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.
    Kapidzic A; van der Meulen MP; Hol L; van Roon AH; Looman CW; Lansdorp-Vogelaar I; van Ballegooijen M; van Vuuren AJ; Reijerink JC; van Leerdam ME; Kuipers EJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1464-71.e4. PubMed ID: 25724706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
    Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
    Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal hemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia.
    Kim NH; Kwon MJ; Kim HY; Lee T; Jeong SH; Park DI; Choi K; Jung YS
    Dig Liver Dis; 2016 Jun; 48(6):667-72. PubMed ID: 27012445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.
    Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
    Dig Liver Dis; 2018 Mar; 50(3):254-259. PubMed ID: 29198569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia.
    Kim NH; Lim JW; Kim S; Lim JY; Kim W; Park JH; Park DI; Sohn CI; Jung YS
    Dig Liver Dis; 2019 Apr; 51(4):589-594. PubMed ID: 30733186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens.
    Wong MC; Ching JY; Chan VC; Lam TY; Shum JP; Luk AK; Wong SS; Ng SC; Ng SS; Wu JC; Chan FK; Sung JJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1472-9. PubMed ID: 25724708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia.
    Lane JM; Chow E; Young GP; Good N; Smith A; Bull J; Sandford J; Morcom J; Bampton PA; Cole SR
    Gastroenterology; 2010 Dec; 139(6):1918-26. PubMed ID: 20723544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantile-based fecal hemoglobin concentration for assessing colorectal neoplasms with 1,263,717 Taiwanese screenees.
    Peng SM; Chiu HM; Jen HH; Hsu CY; Chen SL; Chiu SY; Yen AM; Fann JC; Lee YC; Chen HH
    BMC Med Inform Decis Mak; 2019 May; 19(1):94. PubMed ID: 31046760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program.
    Buron A; Román M; Augé JM; Macià F; Grau J; Sala M; Louro J; Martinez-Alonso M; Alvarez-Urturi C; Andreu M; Bessa X; Zaffalon D; Castells A; Pellisé M; Aldea M; Rivero L; Hernández C; Torá-Rocamora I; Castells X
    Eur J Cancer; 2019 Jan; 107():53-59. PubMed ID: 30544059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.